Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | LPL | P06858 | 1/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.37 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.37 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.37 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29825506 | 1.00 | CA2 (0.42) | CA2LPLLIPGGABRA1GABRG2 | |
| SCHEMBL1138395 | 0.88 | ORAI1 (0.41) | CA2LPLLIPGGABRA1GABRG2 | |
| SCHEMBL29953367 | 0.81 | CA2 (0.42) | CA2LPLLIPGGABRA1GABRG2 | |
| SCHEMBL391628 | 0.81 | CA2 (0.42) | CA2LPLLIPGGABRA1GABRG2 | |
| SCHEMBL1425395 | 0.79 | TSHR (0.41) | CA2 | |
| SCHEMBL29734803 | 0.79 | TSHR (0.41) | CA2 | |
| SCHEMBL41990 | 0.78 | TSHR (0.48) | GABRA1GABRG2GABRB3GABRB2TP53 | |
| SCHEMBL29375771 | 0.78 | TSHR (0.48) | GABRA1GABRG2GABRB3GABRB2TP53 | |
| SCHEMBL29954486 | 0.76 | HSD17B10 (0.54) | CA2HPGD | |
| SCHEMBL15229426 | 0.76 | HSD17B10 (0.54) | CA2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | claimed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | claimed |
| US-20230380457-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-30 | — | — | US | claimed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | claimed |
| US-20230363426-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-16 | — | — | US | claimed |
| US-11793220-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-10-24 | — | — | US | claimed |
| CN-116916755-A | Materials and methods for extending the shelf life of food products | JP实验室公司 | 2023-10-20 | — | — | CN | claimed |
| US-20220264914-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-08-25 | — | — | US | claimed |
| US-20220225647-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | claimed |
| US-20220225646-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | claimed |
| US-20120065404-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | ACTAVIS GROUP PTC HF (IS) | 2012-03-15 | — | — | US | claimed |
| US-8101769-B2 | Chemical intermediate; high purity drug | ACTAVIS GROUP PTC EHF (IE) | 2012-01-24 | — | — | US | claimed |
| US-20100197732-A1 | Repaglinide Substantially Free of Dimer Impurity | ACTAVIS GROUP PTC EHF (IS) | 2010-08-05 | — | — | US | claimed |
| EP-2155706-A2 | REPAGLINIDE SUBSTANTIALLY FREE OF DIMER IMPURITY | Actavis Group PTC EHF (IS) | 2010-02-24 | — | — | EP | claimed |
| EP-2121644-A2 | IMPROVED PROCESS FOR PREPARING ETHYL (S)-2-ETHOXY-4-[N-[1-(2- PIPERIDINOPHENYL)-3-METHYL-1-BUTYL]AMINOCARBONYL METHYL]BENZOATE AND USE THEREOF FOR THE PREPARATION OF REPAGLINIDE | Actavis Group PTC EHF (IS) | 2009-11-25 | — | — | EP | claimed |
| WO-2009004485-A2 | REPAGLINIDE SUBSTANTIALLY FREE OF DIMER IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2009-01-08 | — | — | WO | claimed |
| US-20080200684-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | ACTAVIS GROUP PTC HF (IS) | 2008-08-21 | — | — | US | claimed |
| WO-2008099286-A2 | IMPROVED PROCESS FOR PREPARING ETHYL (S)-2-ETHOXY-4-[N-[1-(2- PIPERIDINOPHENYL)-3-METHYL-1-BUTYL]AMINOCARBONYL METHYL]BENZOATE AND USE THEREOF FOR THE PREPARATION OF REPAGLINIDE | ACTAVIS GROUP PTC EHF (US) | 2008-08-21 | — | — | WO | claimed |
| US-12624032-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2026-05-12 | — | — | US | disclosed |
| WO-1992016519-A2 | ANISOTROPIC ORGANIC COMPOUNDS | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197732-A1 | Repaglinide Substantially Free of Dimer Impurity | EMG1, DAP3, DRD4 | CA2 4632/4885LPL 2871/4885LIPG 3913/4885 |
| US-20120065404-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | MEP1B, GABRE, BPGM | CA2 3520/4885LPL 1481/4885LIPG 1079/4885 |
| US-12624032-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | RIPK2, RIPK1, RIPK4 | CA2 1983/4885LPL 2992/4885LIPG 2825/4885 |
| US-20080200684-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | MEP1B, GABRE, BPGM | CA2 3520/4885LPL 1481/4885LIPG 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.